Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.
Blockade of opioidergic neurotransmission contributes to reduction in body weight. However, how such blockade affects body weight gain (BWG) attributed to second generation antipsychotic agents (SGAs) has not yet been established. Here we examined the effects of an opioid receptor antagonist, naltrexone (NTX), on food intake and BWG associated with an SGA, olanzapine (OL). Four groups of Wistar Han IGS rats were treated for 28 days with either OL (2 mg/kg twice daily, intraperitoneal (IP)), a combination of OL (2 mg/kg twice daily, IP) + extended-release NTX (50 mg/kg, one-time, intramuscular (IM)), extended-release NTX (50 mg/kg, one-time, IM) or vehicle and their food intake and body weight were measured daily for the first nine days and every other day thereafter. Food intake and BWG that were increased by OL were decreased by the added NTX while NTX alone had no significant effects on food intake or on BWG. Plasma leptin concentrations were significantly elevated in the three groups receiving pharmacological agents, but did not differ among each other, suggesting that changes in leptin secretion and/or clearance alone would not explain the food intake and the body weight findings. Our results extend prior reports on anorexigenic effects of opioid antagonists by demonstrating that such effects may generalize to food intake increases and BWG arising in the context of OL pharmacotherapy.
Technion-Israel Institute of Technology, Haifa, Israel.
Daniel B
DB
Kurbanov
Paul J
PJ
Currie
Donald C
DC
Simonson
David
D
Borsook
Igor
I
Elman
D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001067:Appetite Depressants / Q000008:administration & dosage / Q000494:pharmacology*; D001069:Appetite Regulation / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D004347:Drug Interactions; D002149:Energy Intake / Q000187:drug effects*; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D020738:Leptin / Q000097:blood; D009271:Naltrexone / Q000008:administration & dosage / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000077152:Olanzapine; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D001067:Appetite Depressants; D003692:Delayed-Action Preparations; D020738:Leptin; D009292:Narcotic Antagonists; D001569:Benzodiazepines; D009271:Naltrexone; D000077152:Olanzapine